LONDON – A year on from delivering positive phase IIb data, Oculis SA has raised $57 million in an oversubscribed series C, to take OCS-01, a topical nanoparticle formulation of dexamethasone, through two phase III trials.
Ceribell Inc. amassed $53 million in a series C fundraising round to broaden the footprint for its noninvasive brain monitor in U.S. hospitals and expand indications for its Rapid Response EEG. Longitude Capital and The Rise Fund led the round.
Being in a crowded space doesn’t bother recently installed Arch Oncology Inc. CEO Laurence Blumberg. As a matter of fact, he’s reassured by it. “There’s a lot of competition in CD47, that’s correct,” Blumberg told BioWorld. “But having been in industry for a long time, competition and the magnitude of that competition in pursuit of a target usually means there’s a good reason for that interest and that there’s compelling evidence it has utility.”